CWP
NTLA icon

Concord Wealth Partners’s Intellia Therapeutics NTLA Stock Holding History

Concord Wealth Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3
Closed -$105 – 1149
2022
Q4 		$105 Buy
+3
New +$143 ﹤0.01% 1223
2022
Q3 		– Sell
-366
Closed -$19K – 787
2022
Q2 		$19K Sell
366
-1,401
-79% -$71.1K 0.01% 555
2022
Q1 		$128K Sell
1,767
-24
-1% -$2.03K 0.03% 258
2021
Q4 		$212K Buy
1,791
+1,322
+282% +$166K 0.05% 178
2021
Q3 		$63K Sell
469
-1,101
-70% -$167K 0.03% 182
2021
Q2 		$254K Buy
1,570
+241
+18% +$18.8K 0.07% 113
2021
Q1 		$107K Buy
1,329
+1,282
+2,728% +$86.1K 0.04% 206
2020
Q4 		$3K Buy
+47
New +$1.71K ﹤0.01% 481

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Concord Wealth Partners's NTLA Position: Q1 2023 in Review

Concord Wealth Partners sold out of Intellia Therapeutics (NTLA) in Q1 2023, closing a stake of 3 shares — an estimated $105 sold.

Concord Wealth Partners first reported a position in NTLA in Q4 2020 and held it in 8 quarters. The position peaked at $254K in Q2 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q1 2023.

  • Concord Wealth Partners reported no remaining Intellia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Concord Wealth Partners sold 3 Intellia Therapeutics shares in Q1 2023, an estimated $105.
  • Concord Wealth Partners first reported a position in Intellia Therapeutics in Q4 2020 and held it in 8 quarters.
  • Concord Wealth Partners's Intellia Therapeutics position peaked at $254K in Q2 2021.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2023.

Based on Concord Wealth Partners's 13F filing for Q1 2023, filed 26 Apr 2023.